Compare Stocks: TXG, PACB, A, and IQV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
A Agilent Technologies	$169.35 -1.1%	$153.46	$108.35 ▼ $177.05	$47.79B	1.21	2.27 million shs	1.07 million shs
IQV IQVIA	$262.65 -1.3%	$256.23	$154.50 ▼ $277.40	$43.24B	1.17	1.72 million shs	555,806 shs
PACB Pacific Biosciences of California	$2.72 -5.4%	$1.45	$1.07 ▼ $3.44	$850.12M	2.19	7.66 million shs	38.50 million shs
TXG 10x Genomics	$80.83 -17.3%	$66.17	$11.16 ▼ $102.81	$10.61B	1.99	2.91 million shs	6.63 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
A Agilent Technologies	+1.99%	-2.42%	+13.66%	+30.24%	+20.62%
IQV IQVIA	+3.12%	-1.65%	-0.30%	+27.88%	+28.86%
PACB Pacific Biosciences of California	+12.99%	+67.84%	+112.59%	+83.97%	+92.62%
TXG 10x Genomics	+4.53%	+10.44%	+56.01%	+158.37%	+666.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
A Agilent Technologies	$169.35 -1.1%	$153.46	$108.35 ▼ $177.05	$47.79B	1.21	2.27 million shs	1.07 million shs
IQV IQVIA	$262.65 -1.3%	$256.23	$154.50 ▼ $277.40	$43.24B	1.17	1.72 million shs	555,806 shs
PACB Pacific Biosciences of California	$2.72 -5.4%	$1.45	$1.07 ▼ $3.44	$850.12M	2.19	7.66 million shs	38.50 million shs
TXG 10x Genomics	$80.83 -17.3%	$66.17	$11.16 ▼ $102.81	$10.61B	1.99	2.91 million shs	6.63 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
A Agilent Technologies	+1.99%	-2.42%	+13.66%	+30.24%	+20.62%
IQV IQVIA	+3.12%	-1.65%	-0.30%	+27.88%	+28.86%
PACB Pacific Biosciences of California	+12.99%	+67.84%	+112.59%	+83.97%	+92.62%
TXG 10x Genomics	+4.53%	+10.44%	+56.01%	+158.37%	+666.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
A Agilent Technologies	2.80	Moderate Buy	$170.33	0.58% Upside
IQV IQVIA	2.94	Moderate Buy	$264.31	0.63% Upside
PACB Pacific Biosciences of California	1.83	Reduce	$1.71	-36.92% Downside
TXG 10x Genomics	2.28	Hold	$53.93	-33.27% Downside

Current Analyst Ratings Breakdown

Latest TXG, PACB, A, and IQV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	IQV IQVIA	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$345.00
9/30/2026	IQV IQVIA	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/29/2026	TXG 10x Genomics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$40.00 ➝ $90.00
9/29/2026	IQV IQVIA	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$247.00 ➝ $319.00
9/28/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/28/2026	IQV IQVIA	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$300.00 ➝ $329.00
9/28/2026	TXG 10x Genomics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$47.00 ➝ $80.00
9/28/2026	TXG 10x Genomics	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$110.00
9/24/2026	IQV IQVIA	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/21/2026	TXG 10x Genomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	IQV IQVIA	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$240.00 ➝ $270.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
A Agilent Technologies	$7.37B	6.48	$6.69 per share	25.30	$23.78 per share	7.12
IQV IQVIA	$16.98B	2.55	$18.18 per share	14.45	$38.93 per share	6.75
PACB Pacific Biosciences of California	$159.27M	5.30	$0.84 per share	3.22	$0.02 per share	135.75
TXG 10x Genomics	$642.82M	16.38	N/A	N/A	$6.24 per share	12.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
A Agilent Technologies	$1.30B	$5.08	33.37	24.90	2.55	19.53%	24.45%	13.09%	11/23/2026 (Estimated)
IQV IQVIA	$1.36B	$8.06	32.59	20.31	2.21	8.10%	30.25%	6.54%	10/27/2026 (Estimated)
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)
TXG 10x Genomics	-$43.54M	-$0.59	N/A	N/A	N/A	-12.18%	-9.33%	-7.30%	11/5/2026 (Estimated)

Latest TXG, PACB, A, and IQV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	PACB Pacific Biosciences of California	-$0.1260	N/A	N/A	N/A	$43.82 million	N/A
10/27/2026	Q3 2026	IQV IQVIA	$3.27	N/A	N/A	N/A	$4.36 billion	N/A
8/26/2026	Q3 2026	A Agilent Technologies	$1.49	$1.62	+$0.13	$1.28	$1.84 billion	$1.88 billion
8/6/2026	Q2 2026	TXG 10x Genomics	-$0.2431	-$0.14	+$0.1031	-$0.14	$146.67 million	$151.04 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million
7/28/2026	Q2 2026	IQV IQVIA	$3.03	$3.15	+$0.12	$1.53	$4.30 billion	$4.37 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
A Agilent Technologies	$1.02	0.60%	+6.58%	20.08%	9 Years
IQV IQVIA	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
TXG 10x Genomics	N/A	N/A	N/A	N/A	N/A

Latest TXG, PACB, A, and IQV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/16/2026	A Agilent Technologies	quarterly	$0.2550	0.6%	10/6/2026	10/6/2026	10/28/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
A Agilent Technologies	0.50	2.05	1.56
IQV IQVIA	2.18	0.71	0.71
PACB Pacific Biosciences of California	N/A	4.92	4.03
TXG 10x Genomics	N/A	5.69	5.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
A Agilent Technologies	87.41%
IQV IQVIA	89.62%
PACB Pacific Biosciences of California	N/A
TXG 10x Genomics	84.68%

Insider Ownership

Company	Insider Ownership
A Agilent Technologies	0.17%
IQV IQVIA	1.70%
PACB Pacific Biosciences of California	3.70%
TXG 10x Genomics	8.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
A Agilent Technologies	18,100	281.93 million	N/A	Optionable
IQV IQVIA	93,000	164.60 million	161.80 million	Optionable
PACB Pacific Biosciences of California	485	310.83 million	299.33 million	Optionable
TXG 10x Genomics	1,178	130.29 million	118.77 million	Optionable

TXG, PACB, A, and IQV Headlines

Recent News About These Companies

10x Genomics (NASDAQ:TXG) Stock Falls 6.2% - Here's Why

2 hours ago | marketbeat.com

10x Genomics Slides as Rally Cools After Recent Product-Launch Surge

4 hours ago | quiverquant.comQ

10x Genomics (TXG) Starts Atera Shipments And Sentira, Is The Upside Already Priced In?

October 5 at 7:17 PM | finance.yahoo.com

10x Genomics (NASDAQ:TXG) Sets New 52-Week High - Here's What Happened

October 5 at 12:21 PM | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Reaches New 52-Week High - What's Next?

October 5 at 12:19 PM | marketbeat.com

10x Genomics consensus price target raised 12.04% to MX$958.28

October 3 at 2:02 PM | msn.com

10x Genomics consensus price target increased by 13.66% to $60.62

October 2, 2026 | msn.com

10x Genomics $TXG Holdings Trimmed by Versant Capital Management Inc

October 2, 2026 | marketbeat.com

Leerink Partners Sticks to Its Hold Rating for 10x Genomics (TXG)

October 1, 2026 | theglobeandmail.com

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

September 30, 2026 | zacks.com

Atera’s Rapid Commercial Traction and Expanding Product Roadmap Underpin Buy Rating on 10x Genomics

September 29, 2026 | tipranks.com

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

September 29, 2026 | prnewswire.com

10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

September 29, 2026 | prnewswire.com

10x Genomics (NASDAQ:TXG) Sets New 1-Year High - What's Next?

September 28, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) Now Covered by Analysts at Argus

September 28, 2026 | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Stock Picked Up by Analysts at Argus

September 28, 2026 | marketbeat.com

Insider Selling: 10x Genomics (NASDAQ:TXG) Director Sells $464,650.37 in Stock

September 27, 2026 | americanbankingnews.com

Insider Selling: 10x Genomics (NASDAQ:TXG) CEO Sells $2,030,500.00 in Stock

September 27, 2026 | americanbankingnews.com

10x Genomics Insider Sold Shares Worth $464,668, According to a Recent SEC Filing

September 25, 2026 | finance.yahoo.com

10x Genomics (NASDAQ:TXG) Stock: Insider Shehnaaz Suliman Sells 5,723 Shares

September 25, 2026 | insidertrades.com

10x Genomics (NASDAQ:TXG) Stock: Insider Shehnaaz Suliman Sells 5,723 Shares

September 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TXG, PACB, A, and IQV Company Descriptions

Agilent Technologies NYSE:A

$169.34 -1.95 (-1.14%)

As of 03:04 PM Eastern

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

IQVIA NYSE:IQV

$262.65 -3.44 (-1.29%)

As of 03:04 PM Eastern

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Pacific Biosciences of California NASDAQ:PACB

$2.72 -0.16 (-5.40%)

As of 03:04 PM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

10x Genomics NASDAQ:TXG

$80.83 -16.91 (-17.30%)

As of 03:04 PM Eastern

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TXG, PACB, A, and IQV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TXG, PACB, A, and IQV Earnings

Compare Dividends

Latest TXG, PACB, A, and IQV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TXG, PACB, A, and IQV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TXG, PACB, A, and IQV Company Descriptions

Agilent Technologies NYSE:A

IQVIA NYSE:IQV

Pacific Biosciences of California NASDAQ:PACB

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools